Italia Markets closed

PFE Mar 2025 36.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,3400-0,0800 (-19,05%)
In data: 12:42PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,4200
Aperto0,3400
Denaro0,3300
Domanda0,3700
Prezzo d'esercizio36,00
Scadenza2025-03-21
Min-Max giorno0,3300 - 0,3400
Contratto - Min-MaxN/D
Volume117
Open Interest848
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g